share_log

B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42

B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42

Bof A證券將Rhythm Pharmicals的評級下調至中性,將目標股價下調至42美元
Benzinga ·  05/08 06:17

B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral and lowers the price target from $49 to $42.

BofA證券分析師Tazeen Ahmad將Rhythm Pharmaceuticals(納斯達克代碼:RYTM)的評級從買入降至中立,將目標價從49美元下調至42美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論